Galeano Valle, Francisco

Profile Picture
First Name
Last Name
Galeano Valle
Universidad Complutense de Madrid
Faculty / Institute
UCM identifierScopus Author IDDialnet ID

Search Results

Now showing 1 - 2 of 2
  • Publication
    Mid-Regional Pro-Adrenomedullin, Methemoglobin and Carboxyhemoglobin as Prognosis Biomarkers in Critically Ill Patients with COVID-19: An Observational Prospective Study
    (MDPI, 2021-12-06) Oblitas, Crhistian Mario; Galeano Valle, Francisco; Ramírez Navarro, Jesús; López Cano, Jorge; Monterrubio Manrique, Ángel; García Gámiz, Mercedes; Sancho González, Milagros; Arenal López, Sara; Álvarez Sala Walther, Luis Antonio; Demelo Rodríguez, Pablo
  • Publication
    Inflammatory Biomarkers in the Short-Term Prognosis of Venous Thromboembolism: A Narrative Review
    (MPDI, 2021-03-05) Galeano Valle, Francisco; Ordieres Ortega, Lucía; Oblitas, Crhistian Mario; Toro Cervera, Jorge del; Álvarez-Sala Walther, Luis Antonio; Demelo Rodríguez, Pablo
    The relationship between inflammation and venous thrombosis is not well understood. An inflammatory response may be both the cause and consequence of venous thromboembolism (VTE). In fact, several risk factors of VTE modulate thrombosis through inflammatory markers. Acute pulmonary embolism (PE) is burdened by a remarkable mortality rate, up to 34% in severely ill patients presenting with hemodynamic instability. Initial mortality risk stratification is based on hemodynamic instability. Patients with a situation of hemodynamic stability require immediate further risk assessment based on clinical, imaging, and circulating biomarkers, as well as the presence of comorbidities. Some inflammatory biomarkers have shown potential usefulness in the risk stratification of patients with VTE, especially acute PE. C-reactive protein on admission is associated with 30-day mortality and bleeding in VTE patients. P-selectin is associated with right ventricle dysfunction in PE patients and might be associated with VTE recurrences and the extension of thrombosis. Tissue factor microparticles are associated with VTE recurrence in cancer-associated thrombosis. Other inflammatory biomarkers present scarce evidence (inflammatory cytokines, erythrocyte sedimentation rate, fibrinogen, leukocyte count). In this manuscript, we will review the prognostic role of different inflammatory biomarkers available both for clinical practice and research in VTE patients.